Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial

Stroke

Volumn 29, Issue 1, 1998, Pages 12-17

  Yamaguchi, Takenori ^a   Sano, Keiji ^b   Takakura, Kintomo ^c   Saito, Isamu ^d   Shinohara, Yukito ^e   Asano, Takao ^f   Yasuhara, Hajime ^g  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Fuji Brain Institute and Hospital   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f Department of Internal Medicine   (United States)

^g SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical trials; Neuroprotection; Stroke outcome

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; EBSELEN; GLUTATHIONE PEROXIDASE; HEPARIN; NICARDIPINE; NIFEDIPINE; ORGANOSELENIUM DERIVATIVE; PLACEBO; WARFARIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG GRANULE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INJURY SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPROTECTION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SUSPENSION; TREATMENT OUTCOME; VOMITING;

EID: 0031963836     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.1.12     Document Type: Article

References (23)

1. Müller A, Cadenas E, Graf P, Sies H. A novel biologically active selenoorganic compound, I: glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem Pharmacol. 1984;33:3235-3239.
2. Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R. A novel biologically active seleno-organic compound, II: activity of PZ51 in relation to glutathione peroxidase. Biochem Pharmacol. 1984;33:3241-3245.
3. Maiorino M, Roveri A, Coassin M, Ursini F. Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51). Biochem Pharmacol. 1988;37:2267-2271.
4. Müller A, Gabriel H, Sies H. A novel biologically active selenoorganic compound, IV: protective glutathione-dependent effect of PZ 51 (ebselen) against ADP-Fe induced lipid peroxidation in isolated hepatocytes. Biochem Pharmacol. 1985;34:1185-1189.
5. Safayhi H, Tiegs G, Wendel A. A novel biologically active seleno-organic compound, V: inhibition by ebselen (PZ 51) of rat peritoneal neutrophil lipoxygenase. Biochem Pharmacol. 1985;34:2691-2694.
6. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia, part II: mechanisms of damage and treatment. J Neurosurg. 1992;77:337-354.
7. Hall ED, Braughler JM. Central nervous system trauma and stroke, II: physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med. 1989;6:303-313.
8. Johshita H, Sasaki T, Matsui T, Hanamura T, Masayasu H, Asano T, Takakura K. Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta Neurochir (Wien), 1990;51:239-241.
9. Dawson DA, Masayasu H, Graham DI, Macrae IM. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett. 1995;185:65-69.
10. Matsui T, Johshita H, Asano T, Tanaka J. Effect of a free radical scavenger, ebselen, on cerebral ischemia. In: Krieglstein J, Oberpichler H, eds. Pharmacology of Cerebral Ischemia. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH; 1990:363-367.
11. Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol. 1997;122: 1251-1256.
12. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1-9.
13. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81-84.
14. Ohta T, Kikuchi H, Hashi K, Kudo Y. Nizofenone administration in the acute stage following subarachnoid hemorrhage. J Neurosurg. 1986;64:420-426.
15. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet. 1975;1:480-484.
16. Gelmers HJ, Gorter K, Weerdt CJ, Wiezer HJA. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med. 1988;318:203-207.
17. Stah S, Vanclay F, Cooper B. Predicting discharge status at commencement of stroke rehabilitation. Stroke. 1989;20:766-769.
18. Zini I, Tomasi A, Grimaldi R, Vannini V, Agnati LF. Detection of free radicals during brain ischemia and reperfusion by spin trapping and microdialysis. Neurosci Lett. 1992;138:279-282.
19. Ullrich V, Weber P, Meisch F, Appen F. Ebselen-binding equilibria between plasma and target proteins. Biochem Pharmacol. 1996;52:15-19.
20. Ichikawa S, Omura K, Katayama T, Okamura N, Ohtsuka T, Ishibashi S, Masayasu H. Inhibition of superoxide anion production in guinea pig polymorphonuclear leukocytes by a seleno-organic compound, ebselen. J Pharmacobio-Dyn. 1987;10:595-597.
21. Hattori R, Inoue R, Sase K, Eizawa H, Kosuga K, Aoyama T, Masayasu H, Kawai C, Sasayama S, Yui Y. Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur J Pharmacol. 1994;267:R1-R2.
22. Masumoto H, Sies H. The reaction of ebselen with peroxynitrite. Chem Res Toxicol. 1996;9:262-267.
23. Nozawa R, Arai M, Kuruto R, Motohashi T, Masayasu H. Susceptibility of mice to bacterial and fungal infections after intragastric administration of ebselen. J Pharm Pharmacol. 1996;48:64-67.